ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 927,62
0,44%
Dow Jones
44 424,25
-0,32%
DAX
21 394,93
-0,11%
Brent Oil
77,115
-0,09%
Bitcoin
101 444,32
-1,19%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. ATAI Life Sciences NV (ATAI) Cours

ATAI Life Sciences NV

ATAI Life Sciences NV (ATAI)

NASDAQ
1,58
0,07
(4,64%)
Fermé 27 Janvier 10:00PM
Retardé de 15 minutes
1,5853
0,0053
(0,34%)
Après les heures de négociation: 1:58AM
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
1,5853
Prix Achat
1,55
Prix Vente
1,57
Volume échangé
1 435 439
1,48 Fourchette du Jour 1,635
1,03 Plage de 52 semaines 2,85
Cap du marché
266,017M
Clôture Veille
1,51
Ouverture
1,51
Dernière Transaction
75
@
1.58
Dernière heure de transaction
Volume financier
US$ 2 262 552
VWAP
1,5762
Volume moyen (3 m)
1 807 504
Actions en circulation
167 802 396
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-6,55
Bénéfice par action (BPA)
-0,24
Chiffre d'affairess
314k
Bénéfice net
-40,22M

À propos de ATAI Life Sciences NV

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA d... ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany. Show more

Secteur
Intermediate Care Facilities
Industrie
Intermediate Care Facilities
Site Web
www.atai.life
Siège social
Berlin, Deu
Fondé
-
ATAI Life Sciences NV est coté dans le secteur Intermediate Care Facilities de la NASDAQ avec le ticker ATAI. Le dernier cours de clôture d'ATAI Life Sciences NV était de US$1,51. Au cours de la dernière année, les actions de ATAI Life Sciences NV ont été négociées dans une fourchette de prix de US$ 1,03 à US$ 2,85.

ATAI Life Sciences NV compte actuellement 167 802 396 actions en circulation. La capitalisation boursière d'ATAI Life Sciences NV est de US$253,38 million. ATAI Life Sciences NV a un ratio cours/bénéfice (ratio PE) de -6.55.

ATAI Dernières nouvelles

Plus de nouvelles

Form 8-K - Current report

24 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 Janvier 2025
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

10 Janvier 2025
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

10 Janvier 2025
Edgar (US Regulatory)

Form 8-K - Current report

10 Janvier 2025
Edgar (US Regulatory)

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd...

10 Janvier 2025
GlobeNewswire Inc.

Form 3 - Initial statement of beneficial ownership of securities

13 Décembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

13 Novembre 2024
Edgar (US Regulatory)

atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to initiate a Phase 2 study in treatment-resistant...

13 Novembre 2024
GlobeNewswire Inc.

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial...

11 Novembre 2024
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.195314.05035971221.391.61.38638859071.49081131CS
40.315424.83660130721.26991.911.2118372261.5575668CS
120.525349.55660377361.061.951.0518075041.50509887CS
26-0.0147-0.918751.61.951.0311202541.42584461CS
52-0.2847-15.22459893051.872.851.0311978251.68256746CS
156-3.4397-68.45174129355.0256.321.02510519332.30661027CS
260-0.2447-13.37158469951.8322.911.0258263803.42531412CS

ATAI - Frequently Asked Questions (FAQ)

What is the current ATAI Life Sciences NV share price?
The current share price of ATAI Life Sciences NV is US$ 1,5853
How many ATAI Life Sciences NV shares are in issue?
ATAI Life Sciences NV has 167 802 396 shares in issue
What is the market cap of ATAI Life Sciences NV?
The market capitalisation of ATAI Life Sciences NV is USD 253,38M
What is the 1 year trading range for ATAI Life Sciences NV share price?
ATAI Life Sciences NV has traded in the range of US$ 1,03 to US$ 2,85 during the past year
What is the PE ratio of ATAI Life Sciences NV?
The price to earnings ratio of ATAI Life Sciences NV is -6,55
What is the cash to sales ratio of ATAI Life Sciences NV?
The cash to sales ratio of ATAI Life Sciences NV is 826,32
What is the reporting currency for ATAI Life Sciences NV?
ATAI Life Sciences NV reports financial results in USD
What is the latest annual turnover for ATAI Life Sciences NV?
The latest annual turnover of ATAI Life Sciences NV is USD 314k
What is the latest annual profit for ATAI Life Sciences NV?
The latest annual profit of ATAI Life Sciences NV is USD -40,22M
What is the registered address of ATAI Life Sciences NV?
The registered address for ATAI Life Sciences NV is WALLSTRABE 16, BERLIN, 10179
What is the ATAI Life Sciences NV website address?
The website address for ATAI Life Sciences NV is www.atai.life
Which industry sector does ATAI Life Sciences NV operate in?
ATAI Life Sciences NV operates in the INTERMEDIATE CARE FACILITIES sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
NVNINVNI Group Ltd
US$ 4,38
(193,96%)
366,98M
EVAXEvaxion Biotech AS
US$ 5,99
(64,56%)
55,41M
ELABPMGC Holdings Inc
US$ 3,0901
(56,07%)
76,48M
PCLAPicoCELA Inc
US$ 4,60
(49,35%)
3,75M
GOEVCanoo Inc
US$ 0,475
(43,94%)
282,22M
GODNUGolden Star Acquisition Corporation
US$ 3,11
(-75,82%)
17,51k
GODNGolden Star Acquisition Corporation
US$ 2,93
(-65,67%)
902,76k
NXTTNext Technology Holding Inc
US$ 1,37
(-54,93%)
2,56M
SGLYSingularity Future Technology Ltd
US$ 1,625
(-38,45%)
917,77k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90,11
(-38,07%)
8
ACONAclarion Inc
US$ 0,0557
(28,94%)
811,91M
NVNINVNI Group Ltd
US$ 4,38
(193,96%)
366,98M
RIMEAlgorhythm Holdings Inc
US$ 0,0357
(4,69%)
284,97M
GOEVCanoo Inc
US$ 0,475
(43,94%)
282,22M
NVDANVIDIA Corporation
US$ 142,62
(-3,12%)
232,88M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
ATAI
ATAI Life Sciences NV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés